Y.D. More Investments Ltd Reduces Stock Position in Kamada Ltd. $KMDA

Y.D. More Investments Ltd lessened its stake in Kamada Ltd. (NASDAQ:KMDA) by 52.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 136,438 shares of the biotechnology company’s stock after selling 152,944 shares during the quarter. Y.D. More Investments Ltd’s holdings in Kamada were worth $1,121,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in KMDA. Barclays PLC boosted its stake in Kamada by 417.1% during the fourth quarter. Barclays PLC now owns 4,788 shares of the biotechnology company’s stock worth $34,000 after buying an additional 3,862 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Kamada in the 4th quarter worth $66,000. XTX Topco Ltd purchased a new position in shares of Kamada during the 4th quarter worth $103,000. SIH Partners LLLP purchased a new position in shares of Kamada during the 4th quarter worth $134,000. Finally, Quadrature Capital Ltd boosted its position in shares of Kamada by 53.5% during the 4th quarter. Quadrature Capital Ltd now owns 21,889 shares of the biotechnology company’s stock valued at $155,000 after acquiring an additional 7,627 shares during the last quarter. Hedge funds and other institutional investors own 20.38% of the company’s stock.

Kamada Price Performance

KMDA stock opened at $7.12 on Monday. The business has a fifty day moving average of $7.61 and a two-hundred day moving average of $8.04. The stock has a market cap of $409.47 million, a price-to-earnings ratio of 20.34, a price-to-earnings-growth ratio of 0.65 and a beta of 0.85. Kamada Ltd. has a 52-week low of $6.50 and a 52-week high of $9.35.

Kamada (NASDAQ:KMDA) last posted its earnings results on Thursday, May 14th. The biotechnology company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.05). Kamada had a net margin of 11.21% and a return on equity of 7.73%. The business had revenue of $45.24 million during the quarter, compared to analysts’ expectations of $46.72 million. As a group, sell-side analysts anticipate that Kamada Ltd. will post 0.44 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on KMDA shares. Weiss Ratings lowered shares of Kamada from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, June 25th. Wall Street Zen downgraded shares of Kamada from a “buy” rating to a “hold” rating in a research note on Saturday, May 23rd. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $12.00.

Kamada Company Profile

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma?derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha?1 antitrypsin augmentation therapy approved by the U.S.